Greensboro, NC, November 25, 2025
ProKidney Corp. has sold its Greensboro manufacturing facility, encompassing 210,000 square feet, for $19.5 million, reflecting a $6.5 million loss from its original purchase. This strategic divestment allows ProKidney to focus on enhancing its Phase 3 program and strengthening its Winston-Salem operations. Despite the loss, the company aims to channel resources towards innovation in kidney disease therapies, demonstrating the shifting landscape in healthcare business strategies. Investors will be paying close attention as the company positions itself for future growth.
Greensboro, NC
ProKidney Corp. Sells Greensboro Facility for $19.5 Million
ProKidney Corp. has sold its Greensboro manufacturing facility for $6.5 million less than its original purchase price.
In a strategic move signaling shifts in focus, ProKidney Corp. recently agreed to sell its 210,000-square-foot facility, along with approximately 22 acres of land in Greensboro, North Carolina, to Williams Development Group, LLC for approximately $19.5 million in cash. While the transaction may represent a loss from ProKidney’s earlier investment, it highlights the evolving nature of business strategies as companies adapt to market demands.
ProKidney’s original purchase of the property in June 2023 was for approximately $25.5 million. The subsequent sale reflects a $6.5 million impairment, which has been recognized in the company’s financial statements for 2024. This loss, while significant, may also pave the way for stronger innovation and operational efficiency in the company’s core operations, as it channels resources towards more promising avenues.
Strategic Focus and Future Investments
ProKidney’s decision to divest its Greensboro facility aligns with a broader strategic focus on refining its Phase 3 program and increasing engagement with the FDA to expedite its product’s market entry. Rather than stretching resources across multiple sites, the company is choosing to reinforce its existing infrastructure, particularly its Winston-Salem facility, to better position itself for upcoming commercial demand.
This kind of strategic realignment is not uncommon in the business landscape, especially among companies in the healthcare sector where regulatory challenges and market readiness are paramount. As ProKidney works to refine its proprietary REnal Autologous Cell Therapy, REACT®, currently in Phase 3 development, it stands to benefit from concentrated investments that enhance operational capabilities.
ProKidney Corporation Overview
ProKidney Corp. is recognized as a late clinical-stage cellular therapeutics organization dedicated to preserving kidney function for patients suffering from chronic kidney disease. The need for innovative solutions in this area has never been more critical, and the company’s commitment to developing advanced treatments is commendable. With cash, cash equivalents, and marketable securities totaling $358.3 million reported as of October 2025, ProKidney aims to sustain operations into mid-2027, underscoring its stable financial footing amidst transitions.
With a current trading price of $2.14 per share, which has seen a decrease of $0.05 (-2.28%) from the previous close, ProKidney’s stock performance will certainly be monitored closely by investors as the company works towards revitalizing its market presence.
Conclusion
The recent sale of the Greensboro facility presents a mix of challenges and opportunities for ProKidney Corp. While the $6.5 million loss from the sale is significant, the strategic pivot likely positions the company for enhanced growth and innovation in meeting chronic kidney disease needs. It serves as a reminder for local entrepreneurs and businesses in Charlotte and beyond to stay agile and focused, adapting to market realities and regulatory landscapes to foster both individual and community success.
As ProKidney refocuses its efforts, local stakeholders are encouraged to continue supporting innovative companies in North Carolina, ensuring that the entrepreneurial spirit thrives and that economic growth remains robust throughout the region.
What was the sale price of ProKidney’s Greensboro facility?
ProKidney sold the facility for approximately $19.5 million in cash.
How much did ProKidney originally pay for the Greensboro property?
The company initially purchased the property for approximately $25.5 million in cash.
What was the financial impact of the sale on ProKidney?
The sale resulted in a $6.5 million loss compared to the original purchase price, recognized as an impairment charge in the company’s financial statements for the year ended December 31, 2024.
Why did ProKidney decide to sell the Greensboro facility?
The decision aligns with ProKidney’s strategic focus on refining its Phase 3 program and engaging in discussions with the FDA to accelerate its product’s path to market. The company plans to invest in its existing Winston-Salem facility to meet potential commercial demand.
What is ProKidney Corp.?
ProKidney Corp. is a late clinical-stage cellular therapeutics company focused on preserving kidney function in patients with chronic kidney disease.
| Feature | Details |
|---|---|
| Sale Price | Approximately $19.5 million in cash |
| Original Purchase Price | Approximately $25.5 million in cash |
| Financial Impact | $6.5 million loss recognized as an impairment charge |
| Strategic Focus | Refining Phase 3 program and FDA discussions to accelerate product’s market path |
| Company Overview | Late clinical-stage cellular therapeutics company focused on preserving kidney function in chronic kidney disease patients |
| Stock Performance | Trading at $2.14 per share, down $0.05 (-2.28%) from previous close |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: HERE Charlotte
The CHARLOTTE STAFF WRITER represents the experienced team at HERECharlotte.com, your go-to source for actionable local news and information in Charlotte, Mecklenburg County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Lovin' Life Music Festival, Charlotte Pride festival, and major sporting tournaments at Bank of America Stadium. Our coverage extends to key organizations like the Charlotte Regional Business Alliance and Foundation for the Carolinas, plus leading businesses in finance and entertainment that power the local economy such as Bank of America and NASCAR. As part of the broader HERE network, including HEREAsheville.com, HEREGreensboro.com, HERERaleigh.com, and HEREOBX.com, we provide comprehensive, credible insights into North Carolina's dynamic landscape.
